نتائج البحث - "Brian Sharkey"

1

Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study

المؤلفون: Victoria Werth, Marilyn Pike, Joan Merrill, Eric Morand, Ronald Van Vollenhoven, Coburn Hobar, Nikolay Delev, Vaishali Shah, Brian Sharkey, Thomas Wegman, Ian Catlett, Subhashis Banerjee, Shalabh Singhal

المصدر: SKIN The Journal of Cutaneous Medicine. 7:s114

مصطلحات موضوعية: Dermatology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::04e36227a2704f7767f492960ee76ae9Test
https://doi.org/10.25251/skin.7.supp.114Test

2

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial

المؤلفون: Eric Morand, Marilyn Pike, Joan T. Merrill, Ronald van Vollenhoven, Victoria P. Werth, Coburn Hobar, Nikolay Delev, Vaishali Shah, Brian Sharkey, Thomas Wegman, Ian Catlett, Subhashis Banerjee, Shalabh Singhal

المساهمون: Clinical Immunology and Rheumatology, AII - Inflammatory diseases, AMS - Musculoskeletal Health, Rheumatology

المصدر: Arthritis and Rheumatology. John Wiley and Sons Ltd
Morand, E, Pike, M, Merrill, J T, van Vollenhoven, R, Werth, V P, Hobar, C, Delev, N, Shah, V, Sharkey, B, Wegman, T, Catlett, I, Banerjee, S & Singhal, S 2022, ' Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus : A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial ', Arthritis and Rheumatology . https://doi.org/10.1002/art.42391Test

مصطلحات موضوعية: Rheumatology, Immunology, Immunology and Allergy

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0335c0ff0d29a498d97920776fb7fa70Test
https://pure.amc.nl/en/publications/deucravacitinib-a-tyrosine-kinase-2-inhibitor-in-systemic-lupus-erythematosusTest(bd4a3699-bb65-45a4-8754-6c4571660aad).html

3

965: EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: 12-WEEK RESULTS FROM THE PHASE 2 LATTICE-UC STUDY

المؤلفون: Silvio Danese, Remo Panaccione, Geert R. D'Haens, Laurent Peyrin-Biroulet, Stefan Schreiber, Taku Kobayashi, Beata Gawdis-Wojnarska, Patryk Korga, Humberto Aguilar, Brian Sharkey, Antoine Sreih, Courtney Radosti, Aditya Patel, James B. Canavan, David T. Rubin

المصدر: Gastroenterology. 162:S-226

مصطلحات موضوعية: Hepatology, Gastroenterology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::e9f7930c24aacd658e9a517d6172044dTest
https://doi.org/10.1016/s0016-5085Test(22)60544-4

4

دورية أكاديمية

Heat Illness Basics for Wildland Firefighters

المؤلفون: Forest Service, Joe Domitrovich, Brian Sharkey

المساهمون: The Pennsylvania State University CiteSeerX Archives

المصدر: http://www.fs.fed.us/fire/safety/heat-illness.pdfTest.

مصطلحات موضوعية: Sweat gland

وصف الملف: application/pdf

العلاقة: http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.366.8879Test; http://www.fs.fed.us/fire/safety/heat-illness.pdfTest

الإتاحة: http://www.fs.fed.us/fire/safety/heat-illness.pdfTest

View record in BASE

5

Estimation of the cumulative incidence function under multiple dependent and independent censoring mechanisms

المؤلفون: Michael Hughes, Shu Yang, Judith J. Lok, Brian Sharkey

المصدر: Lifetime Data Analysis. 24:201-223

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ec2917c78ad83ac43eba00825234777Test
https://doi.org/10.1007/s10985-017-9393-4Test

6

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

المصدر: Journal of Translational Medicine

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8be7ac479acdaec2aefbcf2c605055ddTest
https://doi.org/10.1186/1479-5876-13-s1-o6Test

7

Nivolumab in previously untreated melanoma without BRAF mutation

المصدر: Robert, C, Long, G V, Brady, B, Dutriaux, C, Maio, M, Mortier, L, Hassel, J C, Rutkowski, P, McNeil, C, Kalinka-Warzocha, E, Savage, K J, Hernberg, M M, Lebbé, C, Charles, J, Mihalcioiu, C, Chiarion-Sileni, V, Mauch, C, Cognetti, F, Arance, A, Schmidt, H, Schadendorf, D, Gogas, H, Lundgren-Eriksson, L, Horak, C, Sharkey, B, Waxman, I M, Atkinson, V & Ascierto, P A 2015, ' Nivolumab in previously untreated melanoma without BRAF mutation ', The New England Journal of Medicine, vol. 372, no. 4, pp. 320-30 . https://doi.org/10.1056/NEJMoa1412082Test
New England Journal of Medicine; 372(4), pp 320-330 (2015)